Company profile: Evitria
1.1 - Company Overview
Company description
- Provider of global antibody expression services specialized in CHO-based transient production of recombinant antibodies, including chimeric, bispecific, Fc-optimized, fusion, afucosylated (GlymaxX) and Fc-silenced (STR) variants. Offers bispecific formats (Duobody, IgG-scFvs, Knobs-into-Holes) and transient expression of secreted proteins (scFvs, extracellular domains, cytokines, viral proteins).
Products and services
- Recombinant Antibody Production: evitria constructs recombinant antibodies in vitro—chimeric, bispecific, Fc-optimized, and fusion—supported by more than 30,000 transfections and 5,000 antibody-based molecules experience (CHO-based)
- Bispecific Antibody Expression: evitria architects antibodies engaging two target antigens simultaneously using Duobody, IgG-scFvs, and Knobs-into-Holes formats (multi-format)
- Afucosylated Antibodies: evitria produces antibodies with low fucose content to enhance ADCC activity using ProBioGen’s GlymaxX technology (glycoengineered)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Evitria
Applied BioCode
HQ: United States
Website
- Description: Provider of multiplex molecular diagnostic systems and panels for clinical testing, life science research, medicine, and AgBio. Offerings include the BioCode® MDx-3000 automated, high-throughput system and assays such as the BioCode® Gastrointestinal and Respiratory Pathogen Panels, BioCode® STI + Resistance Panel, BioCode® CoV-2 Flu Plus Assay, and BioCode® SARS-CoV-2 Assay.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied BioCode company profile →
Lunaphore
HQ: Switzerland
Website
- Description: Provider of chip-based spatial biology solutions that extract spatial proteomic and transcriptome data from tumors and other tissues, transforming any assay into multiplex spatial biology via an easy-to-use interface. Products include COMET, a fully automated high-throughput hyperplex platform integrating staining, imaging, and image preprocessing, and HORIZON, image analysis software for hyperplex immunofluorescence and cell-based analysis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lunaphore company profile →
Cellular Highways
HQ: United Kingdom
Website
- Description: Provider of microfluidic cell sorting solutions for research and clinical applications, including Highway1, a fluorescence-based sterile GMP benchtop sorter with Windows host PC and single-use cartridges; mAIvis automated imaging software; VACS thermal vapour bubble vortex deflection; GMP cell sorting systems, sterile GMP cartridges, and pilot-scale manufacturing and scaling services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellular Highways company profile →
Aushon Biosystems
HQ: United States
Website
- Description: Provider of robust protein biomarker assay development, detection, and analysis via a multiplex immunoassay platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aushon Biosystems company profile →
PrognomiQ
HQ: United States
Website
- Description: Provider of multi-omics liquid biopsy and proteomic profiling for early disease detection. Offers a platform integrating proteomics, genomics, and metabolomics for early-stage cancers such as lung and pancreatic, large-scale plasma proteomics for biomarker discovery, glycoproteome detection across cancer cohorts, and a multi-omics product pipeline for early detection and treatment of cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PrognomiQ company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Evitria
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Evitria
2.2 - Growth funds investing in similar companies to Evitria
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Evitria
4.2 - Public trading comparable groups for Evitria
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →